Followers | 4053 |
Posts | 151256 |
Boards Moderated | 4 |
Alias Born | 08/05/2009 |
Thursday, December 07, 2023 8:27:25 AM
in between their upcoming Investor call (which usually is a sell on CC day)
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
December 05 2023 - 12:54PM
HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it will host an Investor and Business Update Call on Monday, December 11, 2023, 8:30 a.m. ET. The presentation will be available via teleconference or webcast with audio and presenter-controlled slides.
Webcast Access:
Date: Monday, December 11, 2023
Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)
Webcast URL: https://edge.media-server.com/mmc/p/k7s8zdkg
Recent CYTO News
- Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation • GlobeNewswire Inc. • 05/01/2024 12:47:00 PM
- Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal • GlobeNewswire Inc. • 04/24/2024 12:47:00 PM
- Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 • GlobeNewswire Inc. • 04/04/2024 12:45:00 PM
- Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines • GlobeNewswire Inc. • 03/25/2024 12:47:00 PM
- Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal • GlobeNewswire Inc. • 02/07/2024 01:47:00 PM
- Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment • GlobeNewswire Inc. • 01/24/2024 01:47:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/22/2024 10:02:55 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/22/2024 05:15:31 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/19/2024 09:45:26 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/19/2024 09:40:50 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/19/2024 09:30:47 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 01/08/2024 10:02:56 PM
- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit • GlobeNewswire Inc. • 01/08/2024 01:47:00 PM
- Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 12/29/2023 01:47:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2023 01:01:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2023 01:00:31 PM
- Altamira Therapeutics Provides Investor and Business Update • GlobeNewswire Inc. • 12/11/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/08/2023 02:00:02 PM
- Altamira Therapeutics to Host Investor & Business Update Call on December 11th • GlobeNewswire Inc. • 12/05/2023 05:54:05 PM
- Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement • GlobeNewswire Inc. • 11/29/2023 03:20:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/22/2023 09:30:39 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2023 01:00:23 PM
- Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business • GlobeNewswire Inc. • 11/17/2023 02:04:00 PM
- Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine • GlobeNewswire Inc. • 11/10/2023 01:47:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM